



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: McKearn et al.

GROUP ART UNIT: 1624

SERIAL NO.: 09/857,995

EXAMINER: Sudhaker B. Patel

FILED: 5 October 2001

DOCKET NO.: 3167/SZ

FOR: METHOD OF USING MMP INHIBITORS AND ONE OR MORE
ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE
TREATMENT OF NEOPLASIA

1 of 2
RECEIVED

APR 30 2003

TECH CENTER 1600/2900 22

Provisional Terminal Disclaimer

The owner*, Pharmacia Corporation, of all right, title, and interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/843,132, filed on 25 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. The undersigned is an attorney or agent of record.

06/06/2003 PSTANBAC 00000008 09857995

01 FC:1814 110.00 CH

Date: 25 April 2003

Philip B. Polster II
Reg. No. 43,864

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: McKearn et al.

GROUP ART UNIT: 1624

SERIAL NO.: 09/857,995

EXAMINER: Sudhaker B. Patel

FILED: 5 October 2001

DOCKET NO.: 3167/SZ

FOR: METHOD OF USING MMP INHIBITORS AND ONE OR MORE
ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT
OF NEOPLASIA

272
RECEIVED
APR 30 2003
TECH CENTER 1600/2900

Provisional Terminal Disclaimer

The owner*, Pharmacia Corporation, of all right, title, and interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 10/150,546, filed on 16 May 2002, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

05/28/2003 Certificate of Issuance, 09/15/2003
02 FC:1614

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. The undersigned is an attorney or agent of record.

Date: 25 April 2003

Philip B. Polster II
Reg. No. 43,864

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information in this form may become public. Credit card information should not be included in this form. Provide credit card information and authorization on PTO-2038.